Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson's Disease.

Abstract:

:There is escalating interest in cell-based therapies to restore lost dopamine inputs in Parkinson's disease. This is based upon the rationale that implanting dopamine progenitors into the striatum can potentially improve dopamine-responsive motor symptoms. A rich body of data describing clinical trials of previous cell transplantation exists. These have included multiple cell sources for transplantation including allogeneic (human embryonic mesencephalic tissue, retinal pigment epithelial cells) and autologous (carotid body, adrenal medullary tissue) cells, as well as xenotransplantation. However, there are multiple limitations related to these cell sources, including availability of adequate numbers of cells for transplant, heterogeneity within cells transplanted, imprecisely defined mechanisms of action, and poor cell survival after transplantation in some cases. Nonetheless, evidence has accrued from a subset of trials to support the rationale for such a regenerative approach. Recent rapid advances in stem cell technology may now overcome these prior limitations. For example, dopamine neuron precursor cells for transplant can be generated from induced pluripotent cells and human embryonic stem cells. The benefits of these innovative approaches include: the possibility of scalability; a high degree of quality control; and improved understanding of mechanisms of action with rigorous preclinical testing. In this review, we focus on the potential for cell-based therapies in Parkinson's disease to restore the function of dopaminergic neurons, we critically review previous attempts to harness such strategies, we discuss potential benefits and predicted limitations, and we address how previous roadblocks may be overcome to bring a cell-based approach to the clinic.

journal_name

CNS Drugs

journal_title

CNS drugs

authors

Henchcliffe C,Sarva H

doi

10.1007/s40263-020-00727-3

subject

Has Abstract

pub_date

2020-06-01 00:00:00

pages

559-577

issue

6

eissn

1172-7047

issn

1179-1934

pii

10.1007/s40263-020-00727-3

journal_volume

34

pub_type

杂志文章
  • Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action.

    abstract::The aim of this review is to provide clinicians with a picture of the mechanisms by which: histamine and histaminergic agonists act on the vestibular system both peripherally and centrally; and histaminergic agonists and antagonists interfere with the recovery process after peripheral vestibular lesion. We have focuse...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115110-00004

    authors: Lacour M,Sterkers O

    更新日期:2001-01-01 00:00:00

  • Pregabalin: as adjunctive treatment of partial seizures.

    abstract::Pregabalin, the pharmacologically active S-enantiomer of 3-aminomethyl-5-methylhexanoic acid, possesses anticonvulsant activity. Pregabalin binds with high affinity and specificity to voltage-gated calcium channel alpha(2)-delta proteins. The putative mechanism of action of the drug is reduced excitatory neurotransmit...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519030-00007

    authors: Warner G,Figgitt DP

    更新日期:2005-01-01 00:00:00

  • The new generation of GABA enhancers. Potential in the treatment of epilepsy.

    abstract::gamma-Aminobutyric acid (GABA) is considered to be the major inhibitory neurotransmitter in the brain and loss of GABA inhibition has been clearly implicated in epileptogenesis. GABA interacts with 3 types of receptor: GABAA, GABAB and GABAC. The GABAA receptor has provided an excellent target for the development of d...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115050-00001

    authors: Czuczwar SJ,Patsalos PN

    更新日期:2001-01-01 00:00:00

  • Lacosamide: a review of its use as adjunctive therapy in the management of partial-onset seizures.

    abstract::Lacosamide (Vimpat(®)) is a functionalized amino acid available orally (as a syrup or tablet) and as an intravenous infusion. It is believed to exert its antiepileptic effect by selectively enhancing the slow inactivation of voltage-gated sodium channels. Lacosamide is approved in several countries worldwide as an adj...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0123-5

    authors: Hoy SM

    更新日期:2013-12-01 00:00:00

  • Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.

    abstract:BACKGROUND:Several small studies have shown beneficial effects of ondansetron, a serotonin 5-HT(3) receptor antagonist, in the treatment of obsessive-compulsive disorder (OCD). The efficacy of other 5-HT(3) receptor antagonists in patients with OCD is still unclear. Granisetron does not alter cytochrome P450 activity a...

    journal_title:CNS drugs

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.2165/11635850-000000000-00000

    authors: Askari N,Moin M,Sanati M,Tajdini M,Hosseini SM,Modabbernia A,Najand B,Salimi S,Tabrizi M,Ashrafi M,Hajiaghaee R,Akhondzadeh S

    更新日期:2012-10-01 00:00:00

  • The Therapeutic Role of Gangliosides in Neurological Disorders.

    abstract::Numerous in vitro and in vivo experimental animal studies have demonstrated that gangliosides, particularly GMI ganglioside (siagoside), may stimulate or accelerate the repair of peripheral and central nervous system neurons after various types of damage. Clinical studies of GMl in peripheral neuropathies and stroke, ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199401030-00006

    authors: Schneider JS

    更新日期:1994-03-01 00:00:00

  • Pharmacological management of neuropathic pain following spinal cord injury.

    abstract::Spinal cord injury (SCI) has a number of severe and disabling consequences, including chronic pain, and around 40% of patients develop persistent neuropathic pain. Pain following SCI has a detrimental impact on the patient's quality of life and is a major specific healthcare problem in its own right. Thus far, there i...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200822060-00002

    authors: Baastrup C,Finnerup NB

    更新日期:2008-01-01 00:00:00

  • Prevalence of and change in the prescription of methylphenidate in Israel over a 2-year period.

    abstract:INTRODUCTION:The use of methylphenidate for the treatment of attention deficit-hyperactivity disorder (ADHD) has increased dramatically in the past decade in some countries in Europe and North America. In response to a public debate in Israel, several Knesset members introduced a legislative initiative that aims to lim...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-200317120-00005

    authors: Fogelman Y,Vinker S,Guy N,Kahan E

    更新日期:2003-01-01 00:00:00

  • Spotlight on risperidone in irritability associated with autistic disorder in children and adolescents.

    abstract::Risperidone (Risperdal), a psychotropic atypical antipsychotic agent, is thought to act via dopamine D(2) and serotonin 5-HT(2A) receptor antagonism. The clinical efficacy of oral risperidone in the treatment of bipolar mania and schizophrenia in adult patients is well established. In the US, risperidone is also appro...

    journal_title:CNS drugs

    pub_type: 评论,杂志文章

    doi:10.2165/00023210-200822030-00006

    authors: Scott LJ,Dhillon S

    更新日期:2008-01-01 00:00:00

  • Lisdexamfetamine: A Review in ADHD in Adults.

    abstract::Lisdexamfetamine dimesylate (lisdexamfetamine) is a long-acting amfetamine prodrug with a convenient once-daily oral regimen that offers the potential for improved adherence and reduced abuse compared with short-acting preparations of amfetamines. Lisdexamfetamine (as Elvanse Adult(®); Tyvense Adult™) has been approve...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-016-0327-6

    authors: Frampton JE

    更新日期:2016-04-01 00:00:00

  • Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients.

    abstract:BACKGROUND:Antidepressant-induced liver injury is a major concern and a liver monitoring scheme has been recommended by the European Medicines Agency for agomelatine. OBJECTIVE:The objective of this study was to assess the liver safety and identify the characteristics of patients who developed a significant increase i...

    journal_title:CNS drugs

    pub_type: 杂志文章,meta分析

    doi:10.1007/s40263-016-0351-6

    authors: Perlemuter G,Cacoub P,Valla D,Guyader D,Saba B,Batailler C,Moore K

    更新日期:2016-09-01 00:00:00

  • Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.

    abstract::The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have to consider the potential relevance to the pandemic. Understanding the mechanism of action and the possible idiosyncratic effects of each therapeutic a...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00756-y

    authors: Zheng C,Kar I,Chen CK,Sau C,Woodson S,Serra A,Abboud H

    更新日期:2020-09-01 00:00:00

  • Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder.

    abstract::This review focuses on current information about luteal phase administration (i.e. typically for the last 2 weeks of the menstrual cycle) of pharmacological agents for the treatment of premenstrual dysphoric disorder (PMDD). Compared with continuous administration, a luteal phase administration regimen reduces the exp...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418070-00004

    authors: Freeman EW

    更新日期:2004-01-01 00:00:00

  • Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety.

    abstract:BACKGROUND:Dravet syndrome (DS) is one of the most severe forms of drug-resistant epilepsy and available interventions fail to control seizures in most patients. Cannabidiol (CBD) is the first in a new class of antiepileptic drugs with a distinctive chemical structure and mechanism of action. OBJECTIVE:The aim of this...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00708-6

    authors: Lattanzi S,Brigo F,Trinka E,Zaccara G,Striano P,Del Giovane C,Silvestrini M

    更新日期:2020-03-01 00:00:00

  • Treating depression in children and adolescents: what options now?

    abstract::There have been significant developments in the understanding of depression in children and adolescents in the past few years, including an increased recognition that significant depressive illness occurs in this patient group. Pharmacological and psychotherapeutic treatments are used to manage depression in children ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620010-00001

    authors: Varley CK

    更新日期:2006-01-01 00:00:00

  • A Retrospective Cohort Study of Acute Kidney Injury Risk Associated with Antipsychotics.

    abstract:BACKGROUND:A recent large database analysis raised concerns of potential acute kidney injury (AKI) risk associated with antipsychotics. However, whether individual atypical and typical antipsychotics are associated with differential AKI risks has not been investigated. OBJECTIVE:The current study compared the risks of...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-017-0421-4

    authors: Jiang Y,McCombs JS,Park SH

    更新日期:2017-04-01 00:00:00

  • A naturalistic study of galantamine for Alzheimer's disease.

    abstract:OBJECTIVE:To collect descriptive data on the treatment of Alzheimer's disease with galantamine under naturalistic conditions. STUDY DESIGN:This was a prospective, open-label, observational study. PATIENTS:Subjects (n = 345) with mild to moderately severe dementia of the Alzheimer's type were recruited from 48 hospita...

    journal_title:CNS drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00023210-200620110-00006

    authors: Brodaty H,Woodward M,Boundy K,Barnes N,Allen G,NATURE Investigators.

    更新日期:2006-01-01 00:00:00

  • The risk of stroke in patients with migraine and implications for migraine management.

    abstract::Assessing the risk of stroke in persons with migraine is complicated by the intricate relationship between these two conditions. Both migraine and stroke are common and co-morbidity may, in some cases, be coincidental. Given the overlap of clinical symptoms in stroke and migraine, each condition may also mimic the oth...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519080-00004

    authors: Tietjen GE

    更新日期:2005-01-01 00:00:00

  • Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?

    abstract:BACKGROUND AND OBJECTIVE:Patients with focal seizures recruited into adjunctive antiepileptic drug (AED) trials have become more refractory and severe over time; concurrently, placebo responses have increased. To attempt to account for heterogeneity among trials, propensity-score weighted patient-level data were used t...

    journal_title:CNS drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40263-017-0462-8

    authors: Swallow E,Fang A,Signorovitch J,Plumb J,Borghs S

    更新日期:2017-10-01 00:00:00

  • Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.

    abstract::Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patients with a first cli...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0299-y

    authors: Chan A,de Seze J,Comabella M

    更新日期:2016-01-01 00:00:00

  • Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.

    abstract:INTRODUCTION:Both levetiracetam (LEV) and brivaracetam (BRV) eliminate the electroencephalogram photoparoxysmal response (PPR) in the human phase IIa photosensitivity model of epilepsy. The physiochemical properties of BRV differ from those of LEV, having higher potency and lipophilicity plus 10- to 15-fold greater aff...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00761-1

    authors: Reed RC,Rosenfeld WE,Lippmann SM,Eijkemans RMJC,Kasteleijn-Nolst Trenité DGA

    更新日期:2020-10-01 00:00:00

  • Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders.

    abstract::Alcoholic patients suffer from harmful allostatic neuroplastic changes in the brain causing an acute withdrawal syndrome upon cessation of drinking followed by a protracted abstinence syndrome and an increased risk of relapse to heavy drinking. Benzodiazepines have long been the treatment of choice for detoxifying pat...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0240-4

    authors: Hammond CJ,Niciu MJ,Drew S,Arias AJ

    更新日期:2015-04-01 00:00:00

  • Bipolar depression: management options.

    abstract::Bipolar depression is the predominant abnormal mood state in bipolar disorder. However, despite the key pertinence of this phase of the condition, the focus of research and indeed of clinical interest in the management of bipolar disorder has been mainly on mania. Bipolar depression has been largely neglected, and ear...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317010-00002

    authors: Malhi GS,Mitchell PB,Salim S

    更新日期:2003-01-01 00:00:00

  • Treatment Strategies for Dravet Syndrome.

    abstract::Dravet syndrome (DS) is a medically refractory epilepsy that onsets in the first year of life with prolonged seizures, often triggered by fever. Over time, patients develop other seizure types (myoclonic, atypical absences, drops), intellectual disability, crouch gait and other co-morbidities (sleep problems, autonomi...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0511-y

    authors: Knupp KG,Wirrell EC

    更新日期:2018-04-01 00:00:00

  • Mixed Anxiety and Depression : Diagnosis and Treatment Options.

    abstract::Symptoms of anxiety and depression often appear together in patients, either as 2 discrete disorders, such as major depressive disorder and panic disorder, or as a combination of symptoms not meeting criteria for specific disorders. The social, economic, occupational and medical costs of such comorbid anxiety and depr...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199809040-00003

    authors: Bakish D,Habib R,Hooper CL

    更新日期:1998-04-01 00:00:00

  • A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease.

    abstract:INTRODUCTION:Intranasal (IN) insulin acutely improves verbal memory in mild cognitive impairment (MCI)/Alzheimer's disease (AD), but its therapeutic effects may be attenuated in apolipoprotein E4 (ApoE4) carriers. Furthermore, rapid-acting (RA) insulins may have superior therapeutic effects compared with regular insuli...

    journal_title:CNS drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40263-014-0214-y

    authors: Rosenbloom MH,Barclay TR,Pyle M,Owens BL,Cagan AB,Anderson CP,Frey WH 2nd,Hanson LR

    更新日期:2014-12-01 00:00:00

  • New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential.

    abstract::New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418140-00005

    authors: Connor DF,Steingard RJ

    更新日期:2004-01-01 00:00:00

  • Treatment of epileptic encephalopathies.

    abstract::Epileptic encephalopathy is defined as a condition where the epileptic activity itself may contribute to the severe neurological and cognitive impairment seen, over and above that which would be expected from the underlying pathology alone. The epilepsy syndromes at high risk of this are a disparate group of condition...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0041-6

    authors: McTague A,Cross JH

    更新日期:2013-03-01 00:00:00

  • Pharmacotherapy for parents with attention-deficit hyperactivity disorder (ADHD): impact on maternal ADHD and parenting.

    abstract::Given the high heritability of the disorder, attention-deficit hyperactivity disorder (ADHD) is common among parents of children with ADHD. Parental ADHD is associated with maladaptive parenting, negative parent-child interaction patterns and a diminished response to behavioural parent training. We describe our previo...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/11633910-000000000-00000

    authors: Chronis-Tuscano A,Stein MA

    更新日期:2012-09-01 00:00:00

  • Pharmacological management of postherpetic neuralgia.

    abstract::Postherpetic neuralgia, which occurs most typically in older persons, is one of the most common and serious complications of herpes zoster (or shingles). It is a chronic neuropathic pain syndrome and remains one of the most difficult pain disorders to treat. Known beneficial agents include antidepressants, antiepilept...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317110-00001

    authors: Pappagallo M,Haldey EJ

    更新日期:2003-01-01 00:00:00